NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir […]

Israel-based Alcobra Ltd. (ADHD) said its drug treating Fragile X, a genetic disorder that could lead to autism, failed to meet its primary endpoint in a mid-stage trial.   The company’s stock dropped this morning in response to the news. Shares of Alcobra (ADHD) were down about 13 percent, hitting a low of $6.76 per […]

The NASDAQ temporarily halted sale of San Diego-based Vical (VICL) stock yesterday in anticipation of news regarding its Phase I/II clinical trial for a genital herpes vaccine. Unfortunately, the trial did not meet either of its primary endpoints and trading resumed with a major drop in share prices. The trial was conducted across seven sites […]

LAVAL, Quebec and TARRYTOWN, N.Y., June 23, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that Valeant submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic […]

An experimental anticoagulant drug under joint development between Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) met all primary and secondary endpoints in a Phase III study determining safety and efficacy, the companies jointly announced this morning. The Phase III ANNEXA-A study showed andexanet alfa, an investigational drug that received a breakthrough […]

Germany-based Boehringer Ingelheim announced today positive results from a Phase III RE-VERSE AD clinical trial. The study shows that 5 grams of idarucizumab almost immediately reversed the anticoagulant effect of dabigatran (Pradaxa) in patients who needed it under emergency situations. Study results were also simultaneously published in The New England Journal of Medicine under the […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected […]

Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers. T-cell receptors (TCRs) are a class of compounds that make it easier for the body’s immune cells to mainly identify and then destroy cancer cells. Human papilloma virus […]

The newest HPV vaccine safely and effectively prevents at least four different kinds of cancer in the population recommended to receive it, according to a study in Pediatrics today. Gardasil 9, manufactured by Merck, protects against nine strains of the human papillomavirus, an infection transmitted through direct or indirect contact with the genitals of an […]

SYDNEY, June 22, 2015 /PRNewswire/ — Benitec Biopharma (ASX: BLT; OTCPK: BTEBD) is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company’s proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. The program […]